Please assess the completion status of the following clinical trial:

Trial Title: Greater Trochanteric Pain Syndrome: Efficacy of Ultrasound Guided Platelet-rich Plasma vs Needle Tenotomy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients of both sexes between the ages of 35 and 75 years.~* At the screening visit, they present hip pain at 3 points out of 10 in EVA.~* Body Mass Index values between 20 and 35 (both values included).~* Commitment to comply with all study procedures.~* Diagnoses of chronic GTPS according to the diagnostic criteria that have been previously described.~* The patient must give written informed consent.~* Women of child-bearing age must obtain a negative test result of pregnancy in blood or urine and accept the use of appropriate contraception while in the trial.~Exclusion Criteria:~* • Body Mass Index\>35.~  * Presence of full tendon tear.~ * Systemic autoimmune rheumatologic disease (connective tissue diseases and systemic necrotizing vasculitis)~ * Poorly controlled diabetes mellitus (glycosylated hemoglobin above 9%)~ * Blood disorders (thrombopathy, thrombocytopenia, anemia with Hb \<9)~ * Patients receiving immunosuppressive treatments~ * Treatment by intramuscular corticoid, during the 3 months prior to the first administration of the trial treatment.~ * Treatment with non-steroidal anti-inflammatory drugs (more than 10 days consecutive to usual doses), opiates or oral steroids during the 15 days prior to treatment in the study.~ * Severe heart disease~ * Patients unable to comply with scheduled visits, for work or spend long periods away from their habitual residence.~ * Patients with active cancer or cancer diagnosed in the last five years.~ * Analytical Diagnosis Hepatitis B, C or HIV infection.~ * Pregnant or lactating.~ * People who are taking a drug in clinical investigation or participated in any investigational study clinic (with an authorized or not) within 30 days prior to randomization.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Platelet rich plasma (PRP) (Type: EXPERIMENTAL): 3 mL of autologous platelet rich plasma with a moderate concentration of platelet (2x above peripheral blood) and no leukocytes will be injected under ultrasound guidance
- control (Type: ACTIVE_COMPARATOR): needle tenotomy with lidocaine

Based on this trial design, predict the completion outcome and termination type (if applicable).